TheodoreA.OmachiMD

Critical Care Medicine

Medical Director, Genentech and Volunteer Faculty, UCSF

Dr. Omachi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3333 California St
UCSF Suite 270
San Francisco, CA 94118
Phone+1 475-476-6926

Fax+1 415-814-5770

University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2002 - 2005
University of California San Diego School of MedicineClass of 2002

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

PubMed

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.
Rui Zhu, Rik Schoemaker, Aurelie Gautier, Xianbin Tian, Cheryl HooiMing Sim
British Journal of Clinical Pharmacology. 2024-12-01
3 citations
Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps.
Jessica Braid, Lutaf Islam, Cristian Gugiu, Theodore A Omachi, Helen Doll
The World Allergy Organization Journal. 2023-05-01
1 citations
Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps.
Rui Zhu, Ryan Owen, Justin J. Wilkins, Rik C. Schoemaker, Xianbin Tian
Pulmonary Pharmacology & Therapeutics. 2021-09-28

The Overlap Syndrome Of COPD And OSA: Determinants Of Health Status And OutcomesNational Heart, Lung, And Blood Institute2010–2011
Assessment And Prediction Of Costs And Adverse Health Outcomes In COPDAgency For Healthcare Research And Quality2008